EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
The trademark rights for these brands will be transferred to Lupin by March next year.
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Subscribe To Our Newsletter & Stay Updated
